Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outside sexual partnerships and risk of HIV acquisition for HIV uninfected partners in African HIV serodiscordant partnerships.
Ndase P, Celum C, Thomas K, Donnell D, Fife KH, Bukusi E, Delany-Moretlwe S, Baeten JM; Partners in Prevention HSVHIV Transmission Study Team. Ndase P, et al. Among authors: fife kh. J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):65-71. doi: 10.1097/QAI.0b013e318237b864. J Acquir Immune Defic Syndr. 2012. PMID: 21963939 Free PMC article.
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention.
Mujugira A, Baeten JM, Donnell D, Ndase P, Mugo NR, Barnes L, Campbell JD, Wangisi J, Tappero JW, Bukusi E, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Panteleeff D, Krows M, Shah H, Revall J, Morrison S, Ondrejcek L, Ingram C, Coombs RW, Lingappa JR, Celum C; Partners PrEP Study Team. Mujugira A, et al. Among authors: fife kh. PLoS One. 2011;6(10):e25828. doi: 10.1371/journal.pone.0025828. Epub 2011 Oct 5. PLoS One. 2011. PMID: 21998703 Free PMC article. Clinical Trial.
Partner characteristics predicting HIV-1 set point in sexually acquired HIV-1 among African seroconverters.
Lingappa JR, Thomas KK, Hughes JP, Baeten JM, Wald A, Farquhar C, de Bruyn G, Fife KH, Campbell MS, Kapiga S, Mullins JI, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Lingappa JR, et al. Among authors: fife kh. AIDS Res Hum Retroviruses. 2013 Jan;29(1):164-71. doi: 10.1089/AID.2012.0206. AIDS Res Hum Retroviruses. 2013. PMID: 23061422 Free PMC article. Clinical Trial.
An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention.
Kahle EM, Hughes JP, Lingappa JR, John-Stewart G, Celum C, Nakku-Joloba E, Njuguna S, Mugo N, Bukusi E, Manongi R, Baeten JM; Partners in Prevention HSVHIV Transmission Study and the Partners PrEP Study Teams. Kahle EM, et al. J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):339-47. doi: 10.1097/QAI.0b013e31827e622d. J Acquir Immune Defic Syndr. 2013. PMID: 23187945 Free PMC article.
Plasma viral loads during early HIV-1 infection are similar in subtype C- and non-subtype C-infected African seroconverters.
Campbell MS, Kahle EM, Celum C, Lingappa JR, Kapiga S, Mujugira A, Mugo NR, Fife KH, Mullins JI, Baeten JM; Partners in Prevention HSV/HIV Transmission Study Team. Campbell MS, et al. Among authors: fife kh. J Infect Dis. 2013 Apr;207(7):1166-70. doi: 10.1093/infdis/jit015. Epub 2013 Jan 11. J Infect Dis. 2013. PMID: 23315322 Free PMC article.
Unreported antiretroviral use by HIV-1-infected participants enrolling in a prospective research study.
Kahle EM, Kashuba A, Baeten JM, Fife KH, Celum C, Mujugira A, Essex M, De Bruyn G, Wald A, Donnell D, John-Stewart G, Delany-Moretlwe S, Mugo NR, Farquhar C, Lingappa JR; Partners in Prevention HSVHIV Transmission Study Team. Kahle EM, et al. Among authors: fife kh. J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):e90-4. doi: 10.1097/QAI.0b013e3182a2db02. J Acquir Immune Defic Syndr. 2014. PMID: 24442233 Free PMC article. Clinical Trial. No abstract available.
Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples.
Magaret AS, Mujugira A, Hughes JP, Lingappa J, Bukusi EA, DeBruyn G, Delany-Moretlwe S, Fife KH, Gray GE, Kapiga S, Karita E, Mugo NR, Rees H, Ronald A, Vwalika B, Were E, Celum C, Wald A; Partners in Prevention HSV/HIV Transmission Study Team. Magaret AS, et al. Among authors: fife kh. Clin Infect Dis. 2016 Feb 15;62(4):456-61. doi: 10.1093/cid/civ908. Epub 2015 Nov 17. Clin Infect Dis. 2016. PMID: 26578538 Free PMC article. Clinical Trial.
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.
Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Magaret AS, Wang RS, Kidoguchi L, Barnes L, Ridzon R, Corey L, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Lingappa JR, et al. Among authors: fife kh. Lancet. 2010 Mar 6;375(9717):824-33. doi: 10.1016/S0140-6736(09)62038-9. Epub 2010 Feb 12. Lancet. 2010. PMID: 20153888 Free PMC article. Clinical Trial.
Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.
Baeten JM, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, Wald A, Fife KH, Were E, Mugo N, Sanchez J, Essex M, Makhema J, Kiarie J, Farquhar C, Corey L. Baeten JM, et al. Among authors: fife kh. J Infect Dis. 2011 Jan 1;203(1):117-21. doi: 10.1093/infdis/jiq013. J Infect Dis. 2011. PMID: 21148504 Free PMC article.
127 results